Voyager Therapeutics (VYGR) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Voyager Therapeutics (VYGR) has outperformed Zura Bio (ZURA) over the past year, losing 63.4% versus a loss of 74.4%. Voyager Therapeutics is the larger company by market cap ($95.2 million vs $89.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VYGR | ZURA |
|---|---|---|
| Share price | $1.53 | $0.9305 |
| Market cap | $95.21M | $89.63M |
| 1-day change | -4.97% | -2.30% |
| YTD return | -61.07% | -82.24% |
| 1-year return | -63.40% | -74.37% |
| 5-year return | -50.00% | — |
| EPS (TTM) | $-1.74 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $40.37M | — |
| Revenue growth (YoY) | -49.53% | — |
| Net income (latest FY) | $-119.72M | $-68.65M |
| Operating margin | -326.56% | — |
| Net margin | -296.53% | — |
| 52-week high | $5.48 | $7.44 |
| 52-week low | $1.48 | $0.919 |
| Distance from 52-week high | -72.08% | -87.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +829.41% | +759.75% |
| Average volume | 770.24K | 4.47M |
| Shares outstanding | 62.23M | 96.33M |
| Employees | 141 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VYGR has outperformed ZURA by 11.0 percentage points over the past year.
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
VYGR vs ZURA FAQ
Which is bigger, Voyager Therapeutics or Zura Bio?
Voyager Therapeutics (VYGR) is larger, with a market capitalization of $95.21M compared with $89.63M for Zura Bio (ZURA).
Which stock has performed better over the past year, VYGR or ZURA?
VYGR returned -63.40% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Voyager Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.